Works matching IS 11707690 AND DT 2025 AND VI 43 AND IP 5

Results: 10

Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 469, doi. 10.1007/s40273-025-01480-5

By:

Uteh, Cyril Onwuelazu;
Johnson, Eugenie Evelynne;
Robinson, Tomos;
Moradi, Najmeh;
Inskip, Alex;
Beyer, Fiona R.;
Thomson, Katie;
Sagoo, Gurdeep S.

Publication type:

Article

A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 473, doi. 10.1007/s40273-025-01476-1

By:

Norman, Richard;
Roudijk, Bram;
Jonker, Marcel;
Stolk, Elly;
Knies, Saskia;
Pwu, Raoh-Fang;
O'Neill, Ciaran;
Howard, Kirsten;
Devlin, Nancy

Publication type:

Article

Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation.

Published in:

2025

By:

Gal, Peter;
Feldmajer, Gyorgyi;
Augusto, Margarida;
Gani, Ray;
Hook, Emma;
Bullement, Ash;
Philips, Zoe;
Smith, Inger

Publication type:

Correction Notice

Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 583, doi. 10.1007/s40273-025-01474-3

By:

Zemplenyi, Antal;
Leonard, Jim;
Wright, Garth C.;
DiStefano, Michael J.;
Nair, Kavita;
Anderson, Kelly E.;
McQueen, R. Brett

Publication type:

Article

EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 555, doi. 10.1007/s40273-025-01473-4

By:

Zhou, Wenjing;
Ding, Bo;
Busschbach, Jan;
Herdman, Michael;
Yang, Zhihao;
Lu, Yanming

Publication type:

Article

Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 499, doi. 10.1007/s40273-025-01472-5

By:

Donoghue, Jeremiah;
Youngs, Matthew;
Reeve, Alex;
Vydyula, Krishna;
Kunst, Natalia;
Trikha, Roochi;
Gallacher, Daniel

Publication type:

Article

Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 483, doi. 10.1007/s40273-025-01470-7

By:

Kramer, Astrid;
van Schaik, Lucas F.;
van den Broek, Daan;
Meijer, Gerrit A.;
Gutierrez Ibarluzea, Iñaki;
Galnares Cordero, Lorea;
Fijneman, Remond J. A.;
Ligtenberg, Marjolijn J. L.;
Schuuring, Ed;
van Harten, Wim H.;
Coupé, Veerle M. H.;
Retèl, Valesca P.

Publication type:

Article

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 569, doi. 10.1007/s40273-025-01469-0

By:

Zeevat, Florian;
van der Pol, Simon;
Kieffer, Alexia;
Postma, Maarten J.;
Boersma, Cornelis

Publication type:

Article

Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 521, doi. 10.1007/s40273-024-01467-8

By:

Pick, Georgia;
Müller, Dirk;
Dintsios, Charalabos-Markos

Publication type:

Article

Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice.

Published in:

PharmacoEconomics, 2025, v. 43, n. 5, p. 509, doi. 10.1007/s40273-024-01466-9

By:

Fridhammar, Adam;
Frisell, Oskar;
Wahlberg, Karin;
Berglund, Emelie;
Röbeck, Pontus;
Persson, Sofie

Publication type:

Article